Wouldn't worry too much about it--it's too early to pump this one, and people know it. Still, it's not a bad longer term hold, with trials coming up later this year in 3Q. I'm sure the SP will be higher by then.
Not so much volume, but SP is moving, which indicates that the people holding and buying see potential. Upcoming 3Q phase 1 trial, projected 2016 P3 trial, recent completed private placement, and solid board of directors are all great signs for a long term hold. Still flying way under the radar.
Months ago someone asked Jim about his feelings about Portage on twitter, and he responded that he "likes the people, likes the science" As for being a "friend" of the founders, it's hard to find anyone remotely connected to the industry who doesn't know who Declan Doogan is. He's a good person to know!
No one can convince you to buy it; make your own informed decision. We're witnessing the ground floor of a promising company, but pre-trial, any biotech company is a risk.